5,421 Alnylam Pharmaceuticals, Inc. $ALNY Shares Acquired by ProShare Advisors LLC

ProShare Advisors LLC boosted its stake in Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) by 4.2% during the third quarter, Holdings Channel reports. The institutional investor owned 133,935 shares of the biopharmaceutical company’s stock after buying an additional 5,421 shares during the period. ProShare Advisors LLC’s holdings in Alnylam Pharmaceuticals were worth $33,047,000 as of its most recent filing with the SEC.

A number of other large investors also recently made changes to their positions in the company. Toth Financial Advisory Corp acquired a new stake in Alnylam Pharmaceuticals during the 3rd quarter worth approximately $25,000. Keating Financial Advisory Services Inc. bought a new stake in Alnylam Pharmaceuticals in the 2nd quarter valued at $42,000. Burkett Financial Services LLC acquired a new position in Alnylam Pharmaceuticals in the 3rd quarter valued at $37,000. CoreCap Advisors LLC increased its position in Alnylam Pharmaceuticals by 744.4% during the 3rd quarter. CoreCap Advisors LLC now owns 152 shares of the biopharmaceutical company’s stock worth $38,000 after buying an additional 134 shares during the period. Finally, Ascentis Independent Advisors acquired a new stake in shares of Alnylam Pharmaceuticals during the first quarter worth $64,000. Institutional investors own 92.97% of the company’s stock.

Analysts Set New Price Targets

ALNY has been the subject of a number of recent research reports. Truist Financial reduced their target price on shares of Alnylam Pharmaceuticals from $410.00 to $315.00 and set a “buy” rating for the company in a research report on Tuesday, August 4th. Morgan Stanley lowered their price target on shares of Alnylam Pharmaceuticals from $300.00 to $240.00 and set an “equal weight” rating on the stock in a research report on Friday. Needham & Company LLC dropped their price objective on shares of Alnylam Pharmaceuticals from $357.00 to $243.00 and set a “buy” rating for the company in a research note on Thursday. Stifel Nicolaus downgraded shares of Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating and set a $225.00 price objective for the company. in a report on Thursday. Finally, Raymond James Financial downgraded shares of Alnylam Pharmaceuticals from a “strong-buy” rating to an “outperform” rating and cut their price objective for the company from $420.00 to $315.00 in a report on Friday. One research analyst has rated the stock with a Strong Buy rating, sixteen have assigned a Buy rating and nine have given a Hold rating to the stock. According to data from MarketBeat, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $317.95.

Insiders Place Their Bets

In related news, EVP Bryan Supran sold 1,758 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, October 2nd. The shares were sold at an average price of $226.88, for a total transaction of $398,855.04. Following the completion of the transaction, the executive vice president owned 12,807 shares of the company’s stock, valued at $2,905,652.16. This trade represents a 12.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. The sale was made to cover tax withholding obligations related to the vesting of equity awards. 0.86% of the stock is owned by corporate insiders.

Alnylam Pharmaceuticals News Summary

Here are the key news stories impacting Alnylam Pharmaceuticals this week:

• Positive Sentiment: Quarterly results exceeded expectations. Alnylam reported $16.26 in adjusted earnings per share versus the $1.66 consensus estimate, while revenue rose 16.7% year over year to $1.46 billion, slightly above forecasts. The company maintained its fiscal 2026 product-sales outlook and expects $4.2 billion–$4.5 billion in 2026 TTR sales. Alnylam Q3 earnings beat
• Positive Sentiment: Several analysts still see substantial long-term upside. Chardan Capital, TD Cowen, Goldman Sachs and RBC retained positive ratings, although they reduced their price targets. Their revised targets remain well above the current trading level. Chardan Capital rating
• Neutral Sentiment: Pipeline investment could support future growth but increases execution risk. Alnylam expanded the TRITON-CM nucresiran heart-disease study to approximately 2,250 patients while maintaining an anticipated launch around 2030. Management described its conviction in the program as high, but the longer timeline limits near-term revenue benefits. Alnylam TTR sales and trial update
• Negative Sentiment: Demand-growth concerns overshadowed the earnings beat. Slower Amvuttra patient starts and moderating U.S. Amvuttra and Onpattro sales growth raised concerns that the company’s core TTR business may be losing momentum. Management also acknowledged that it needs to improve execution, adding to uncertainty around the franchise. ALNY demand growth concerns
• Negative Sentiment: Analyst sentiment became more cautious. Bernstein downgraded ALNY to “market perform,” while Stifel cut its rating to “hold.” Multiple firms lowered price targets, including Bernstein from $376 to $199 and Goldman Sachs from $536 to $320, reflecting increased valuation and policy risks.

Alnylam Pharmaceuticals Price Performance

ALNY stock opened at $165.00 on Monday. The company has a fifty day moving average price of $236.49 and a 200-day moving average price of $286.19. The company has a market capitalization of $22.10 billion, a P/E ratio of 8.57 and a beta of 0.43. Alnylam Pharmaceuticals, Inc. has a 52-week low of $163.30 and a 52-week high of $479.79. The company has a debt-to-equity ratio of 0.18, a quick ratio of 2.43 and a current ratio of 2.48.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings data on Thursday, October 29th. The biopharmaceutical company reported $16.26 EPS for the quarter, topping analysts’ consensus estimates of $1.66 by $14.60. The company had revenue of $1.46 billion for the quarter, compared to analyst estimates of $1.43 billion. Alnylam Pharmaceuticals had a return on equity of 155.33% and a net margin of 52.85%. The firm’s quarterly revenue was up 16.7% on a year-over-year basis. During the same period in the previous year, the firm earned $2.90 earnings per share. As a group, equities analysts expect that Alnylam Pharmaceuticals, Inc. will post 6.58 EPS for the current year.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines based on RNA interference (RNAi). The company’s therapies are designed to silence specific genes involved in disease, with the goal of addressing the underlying causes of genetic and other serious conditions.

Alnylam’s marketed products include ONPATTRO (patisiran) and AMVUTTRA (vutrisiran) for hereditary transthyretin-mediated amyloidosis, GIVLAARI (givosiran) for acute hepatic porphyria, and OXLUMO (lumasiran) for primary hyperoxaluria type 1.